News

Renovion, COPD Foundation Partner on New Therapy to Clear Mucus

Renovion is teaming up with the COPD Foundation to develop a new nebulized therapy that aims to help clear mucus and reduce inflammation in people with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis. Phase 2 clinical trials of the investigational treatment, called  ARINA-1, are planned to…

NIH Renews Grant to Research Mechanisms of COPD and IPF

A $12.8 million five-year renewal grant from the National Institutes of Health (NIH) will fund research that seeks to better understand the molecular mechanisms that drive chronic obstructive pulmonary disease (COPD) and other lung diseases. The research also aims to increase understanding of how cigarette smoking affects the development…

Pollution, Distance From Green Spaces Tied to Quality of Life

The health-related quality of life of people with chronic obstructive pulmonary disease (COPD) living in Barcelona, Spain, is negatively affected by exposure to air pollution and living farther away from green or blue water-rich spaces, a study suggests. “This study, performed for the first time on a Mediterranean population,…

How Stem Cell Therapy Works to Ease COPD Described in Study

Treatment with human mesenchymal stem cells (MSCs) results in a strong, but temporary, reduction in pro-inflammatory molecules involved in chronic obstructive pulmonary disease (COPD), according to data from a Phase 1 clinical trial involving nine COPD patients. Notably, molecules directly produced by MSCs were identified as potential drivers of these…

Kaleido, COPD Foundation Partner to Investigate KB109

Kaleido Biosciences is teaming up with the COPD Foundation to investigate KB109, a small compound designed to modulate the gut microbiome — the community of microbes living in the intestines — as a potential treatment for chronic obstructive pulmonary disease (COPD). The decision was based on promising…

AIRFLOW-3 Trial of Targeted Lung Denervation Assigns 100th Patient

One hundred patients have been randomly assigned in Nuvaira’s pivotal AIRFLOW-3 clinical trial that will investigate the efficacy and safety of targeted lung denervation (TLD) to reduce exacerbations, or episodes of symptom worsening, of chronic obstructive pulmonary disease (COPD) in patients on optimal medical care. Because of the…